Chelsea Therapeutics International 8-K 2006
Documents found in this filing:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 6, 2006
CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
13950 Ballantyne Corporate Place, Unit 325, Charlotte, North Carolina 28277
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On September 6, 2006, Chelsea Therapeutics International, Ltd. gave a presentation at the Roth Capital Partners 2006 New York Conference in New York, New York. The Registrant intends to deliver this presentation to various participants in the securities industry. A copy of the presentation is attached hereto as Exhibit 99.1.
Chelsea issued a press release on September 7, 2006 announcing that it has filed its application for Orphan Drug designation with the U.S. FDA and has established a Scientific Advisory Board to provide added guidance for the development and commercialization of Droxidopa. A copy of the press release is attached hereto as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.